Arbutus Biopharma Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk and Volatility

Arbutus Biopharma has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Arbutus Biopharma and Aclaris Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

28.4% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 59.1% of Aclaris Therapeutics shares are held by institutional investors. 6.7% of Arbutus Biopharma shares are held by company insiders. Comparatively, 8.2% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Arbutus Biopharma and Aclaris Therapeutics, as reported by MarketBeat.

Arbutus Biopharma presently has a consensus price target of $6.2857, suggesting a potential upside of 94.00%. Given Arbutus Biopharma's higher possible upside, equities research analysts clearly believe Arbutus Biopharma is more favorable than Aclaris Therapeutics.

Valuation & Earnings

This table compares Arbutus Biopharma and Aclaris Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Arbutus Biopharma has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Arbutus Biopharma beats Aclaris Therapeutics on 9 of the 13 factors compared between the two stocks.

Arbutus Biopharma (NASDAQ:ABUS) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Insider and Institutional Ownership

28.4% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 91.2% of Annexon shares are owned by institutional investors. 6.7% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Arbutus Biopharma and Annexon's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Arbutus Biopharma and Annexon's gross revenue, earnings per share (EPS) and valuation.

Annexon has lower revenue, but higher earnings than Arbutus Biopharma.

Analyst Ratings

This is a summary of current ratings and price targets for Arbutus Biopharma and Annexon, as reported by MarketBeat.

Arbutus Biopharma currently has a consensus target price of $6.2857, suggesting a potential upside of 94.00%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 19.50%. Given Arbutus Biopharma's higher possible upside, equities analysts plainly believe Arbutus Biopharma is more favorable than Annexon.

Summary

Annexon beats Arbutus Biopharma on 5 of the 9 factors compared between the two stocks.

BioXcel Therapeutics (NASDAQ:BTAI) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

48.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 9.4% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 6.7% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for BioXcel Therapeutics and Arbutus Biopharma, as provided by MarketBeat.

BioXcel Therapeutics presently has a consensus price target of $102.00, suggesting a potential upside of 130.77%. Arbutus Biopharma has a consensus price target of $6.2857, suggesting a potential upside of 94.00%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Arbutus Biopharma.

Earnings & Valuation

This table compares BioXcel Therapeutics and Arbutus Biopharma's revenue, earnings per share (EPS) and valuation.

BioXcel Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioXcel Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500.

Profitability

This table compares BioXcel Therapeutics and Arbutus Biopharma's net margins, return on equity and return on assets.

Summary

BioXcel Therapeutics beats Arbutus Biopharma on 7 of the 13 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Valuation & Earnings

This table compares Trillium Therapeutics and Arbutus Biopharma's revenue, earnings per share and valuation.

Trillium Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trillium Therapeutics and Arbutus Biopharma's net margins, return on equity and return on assets.

Insider and Institutional Ownership

67.5% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are held by institutional investors. 6.7% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Trillium Therapeutics and Arbutus Biopharma, as provided by MarketBeat.

Trillium Therapeutics currently has a consensus target price of $21.25, indicating a potential upside of 112.93%. Arbutus Biopharma has a consensus target price of $6.2857, indicating a potential upside of 94.00%. Given Trillium Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Arbutus Biopharma.

Risk and Volatility

Trillium Therapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, indicating that its stock price is 215% more volatile than the S&P 500.

Summary

Trillium Therapeutics beats Arbutus Biopharma on 8 of the 14 factors compared between the two stocks.

Arbutus Biopharma (NASDAQ:ABUS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares Arbutus Biopharma and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Arbutus Biopharma has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Arbutus Biopharma and Enanta Pharmaceuticals, as provided by MarketBeat.

Arbutus Biopharma presently has a consensus price target of $6.2857, indicating a potential upside of 94.00%. Enanta Pharmaceuticals has a consensus price target of $64.6250, indicating a potential upside of 29.53%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Arbutus Biopharma is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Arbutus Biopharma and Enanta Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

28.4% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 6.7% of Arbutus Biopharma shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Arbutus Biopharma's gross revenue, earnings per share (EPS) and valuation.

ORIC Pharmaceuticals has higher earnings, but lower revenue than Arbutus Biopharma.

Profitability

This table compares ORIC Pharmaceuticals and Arbutus Biopharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ORIC Pharmaceuticals and Arbutus Biopharma, as reported by MarketBeat.

ORIC Pharmaceuticals currently has a consensus target price of $43.4286, indicating a potential upside of 34.66%. Arbutus Biopharma has a consensus target price of $6.2857, indicating a potential upside of 94.00%. Given Arbutus Biopharma's higher possible upside, analysts plainly believe Arbutus Biopharma is more favorable than ORIC Pharmaceuticals.

Insider and Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 6.7% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ORIC Pharmaceuticals beats Arbutus Biopharma on 5 of the 8 factors compared between the two stocks.